Status: Recruiting
Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease
The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.
Participants needed: 1,000
Trial details
Age: 19+Biological sex: FemaleType: ObservationalSponsor: Société Algérienne de Formation et Recherche en OncologieUpdated: Apr 21, 2026Locations: 2
Eligibility criteria
Age ≥ 19 years at the time of inclusion; [+4]
Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or fir... [+3]